Abstract 2156
Background
The mobile application is a valuable tool in the transmission of information in terms of having easy access in our daily lives and hosting applications containing information specific to many diseases. After breast cancer surgery, the patients are generally preferred to have verbal expressions in their education. In this context, it is considered that mobile application is the right choice in order to provide the opportunity for the patients to manage their post-operative processes, to facilitate their access to the right information and to provide a positive contribution to their quality of life by providing consultancy services.
Methods
The text content of the mobile application has text, image, video and audio equipment as well as online support / consulting services. It is thought that the mobile application will have a separate interface for each problem, and text and animation content will be the only problem for each interface. Care was taken to ensure that the created interfaces were of different colors and the layout to be used for problem solving was similar for each interface. It was ensured that the patients were checked from the admin panel if they did not watch or watch the videos again. All these operations were entered by entering the user name and password and recorded by end-to-end encryption.
Results
Supporting self-care for a woman who has not yet achieved her responsibility to cope with all responsibilities will contribute to the maintenance of family unity. In the creation of a mobile application that can be reached continuously; It is aimed to support self-care, create a tool that can receive support without any social isolation, decrease individual dependence and increase self-esteem. Thus, the fact that the woman does not have to spend the post-operative period at home and can be used individually and at the desired time constitutes the other advantages of the mobile application.
Conclusions
If the patient with breast surgery has an equipment to support self-care in the post-operative home, it will be possible to decrease the rate of experiencing physiological, psychological and sociological problems. It will be possible for the patient who has no problems to decrease their applications to the hospital and to contribute to the economy of the country.
Clinical trial identification
Legal entity responsible for the study
Aydanur Aydin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract